UNUSUAL SUSPECTS
The factors that I analyzed above do not explain the resistance of biofilms to killing by at least one important group of antimicrobial agents: the fluoroquinolone antibiotics. It has been shown that fluoroquinolones equilibrate across bacterial biofilms. A decreased growth rate contributes to quinolone resistance, but quinolones killed nongrowing planktonic cells of
P. aeruginosa in a simple phosphate buffer, while biofilm cells in a fresh rich medium were more resistant to killing (
11).
Biofilm resistance to killing has generally been assumed to be a feature shared by the bulk of biofilm cells or at least to be present in a sizable part of the population, such as cells in the deeper layers of a thick biofilm, which have less access to nutrients and which will grow more slowly (
15). Resistance to killing by aminoglycosides which have trouble penetrating the biofilm is indeed a shared feature of the bulk of biofilm cells. This, however, is more of an exception rather than the rule. A study of a dose-response killing of
P. aeruginosa biofilms by the quinolones ofloxacin and ciprofloxacin showed that the majority of cells are effectively eliminated by low concentrations of antibiotics, which is not much different from what is observed with planktonic cells. Importantly, the majority of biofilm cells were killed within a clinically achievable range of concentrations (≤5 μg/ml) (
11). However, after an initial 3- to 4-log drop, a further increase in the antibiotic concentration had no effect on killing (Fig.
1). This experiment shows that a small fraction of persister cells is ultimately responsible for the very high level of resistance of the biofilm to killing.
This simple observation suggests a new paradigm for explaining, at least in principle, the phenomenon of biofilm resistance to killing by a wide range of antimicrobials. The majority of cells in a biofilm are not necessarily more resistant to killing than planktonic cells and die rapidly when treated with a cidal antibiotic that can kill slowly growing cells. Persisters survive and are actually preserved by the presence of an antibiotic that inhibits their growth. Paradoxically, the antibiotic helps persisters persevere.
The role of persisters in biofilm resistance to killing has not been considered in the literature prior to our study (
11,
33), but numerous reports over the years show similar biphasic dose-dependent or time-dependent killing of planktonic microbial cells. For example, in
E. coli, increasing concentrations of ciprofloxacin or imipenem caused an initial decrease in the number of live cells of a biofilm by 2 to 3 orders of magnitude, while the remaining small population was essentially insensitive to a further increase in the drug concentration (
4). This pattern was also observed with amoxicillin and clindamycin in
Lactobacillus acidophilus and with erythromycin and metronidazole in the case of
Gardnerella vaginalis biofilms, in which initial rapid killing was followed by a plateau of resistant cells (
43).
It is possible that biofilms produce more persisters than planktonic populations. Increased numbers of persisters, however, are not the main factor responsible for the vastly better survival of biofilms than planktonic cells in vivo. Consider the empirically derived minimal bactericidal concentration (MBC): according to NCCLS guidelines, MBC is the concentration of an antimicrobial agent that results in the lowering of the number of live cells by ≤99.9% after an overnight incubation under growth conditions. The practical reasoning behind this useful but rather arbitrary measure is that killing a majority of pathogens in many cases is just as good as killing them all. This is often the case, because the immune system collaborates with the antibiotics and probably “mops up” the remaining persisters. Persisters do become a problem when the immune system is not operating. For example,
Streptococcus pneumoniae causes recalcitrant meningitis because of the inaccessibility of the cerebrospinal fluid to the components of the immune system. The infection was more pronounced when it was caused by
vncS mutants with increased persistence (tolerance) to a range of antibiotics (
46), and
vncS mutants were isolated from animals with persistent
S. pneumoniae meningitis poorly responding to vancomycin therapy. The gastric environment is similarly devoid of immune factors, and
Helicobacter pylori infection, which causes peptic ulcers, is famously recalcitrant. The gastric environment requires complete sterilization in order to prevent relapses. The presence of persisters that can rebound when the antibiotic concentration drops would explain the necessity of therapy with a combination of unrelated drugs that together probably eradicate persisters (
60; Lynn Silver, personal communication).
Biofilm infections are in a sense very similar to planktonic infections in the absence of an immune response. The biofilm exopolymer physically protects the cells from the components of the immune system (
25,
66). One can envision a biofilm survival dynamic in vivo in which an initial application of a cidal antibiotic eradicates most of the population, leaving a small fraction of surviving persisters (Fig.
2). If the concentration of the antibiotic temporarily drops or if symptoms disappear due to the eradication of planktonic cells and therapy is discontinued, the persisters will reform the biofilm, which will begin to shed off new planktonic cells. This dynamic explains the relapsing nature of biofilm infections and the need for a lengthy antibiotic therapy. This view of a biofilm infection suggests, somewhat counterintuitively, that the recalcitrance of biofilms does not necessarily rely on their higher levels of intrinsic resistance to killing by antibiotics than the level of intrinsic resistance of planktonic cells. Indeed, if a biofilm of a particular species under given conditions in vivo happens to be just as sensitive or even more sensitive to killing by antibiotics than a planktonic population (say, that this biofilm produces fewer persisters than a planktonic population), it will still survive better than planktonic cells, since it is invulnerable to immune attack. This view of biofilm resistance should also alter the current operational definition of an in vitro biofilm that, at least in antimicrobial susceptibility studies, has meant that a cell aggregate on some surface shows increased resistance to killing than a planktonic population. One can suggest, instead, that any cell aggregate that potentially restricts access of host defense components and that produces at least some persister cells can be viewed as a model of a recalcitrant biofilm infection. The proposed criteria will require a susceptibility test to determine if any persisters are present and whether the biofilm under study is capable of restricting penetration across the exopolymer surface. A simple assay for the functionality of the diffusion barrier would be to test the ability of the bulk of the biofilm cells to survive in the presence of an aminoglycoside antibiotic whose penetration is strongly restricted by the matrix, as discussed above. Then a test for susceptibility to killing by a fluoroquinolone like ciprofloxacin to test for the presence of persisters and a test for resistance to killing by an aminoglycoside like tobramycin to test for the diffusion barrier could serve as a straightforward dual-functionality biofilm test for any in vitro biofilm model.
METHODS TO STUDY BIOFILMS
A single standard method for the study of biofilm susceptibility is not available, and this is certainly impeding progress in the field. It is very difficult if not impossible to compare the results obtained with biofilms of even the same species cultured and assayed under vastly different conditions. It is hoped that a unified method will emerge. For now, several methods are available, each with its own advantages and shortcomings, and these will be briefly reviewed. For details, see a recent issue of Methods in Enzymology (volume 310, 1999). The volume also contains descriptions of many useful methods for the study of the biology of biofilms.
A popular method used to study biofilms is the Robbins device (Tyler Instruments, Calgary, Alberta, Canada) that is based on passing a bacterial suspension through a flow cell that has 24 detachable coupons to which cells adhere and grow into a biofilm (
28). Once a biofilm is formed, the feeding liquid can be switched to a culture medium that contains test compounds. After a period of incubation, the device is taken apart and the cells are dislodged by sonication and plated. This method enables reproducible biofilm formation and the observation of biofilm dynamics. The coupons can also be used for microscopic observations of biofilm structure. The strengths of this approach are in the well-controlled conditions that emulate in vivo biofilm formation and in the ability to characterize the formed biofilm by a variety of techniques. However, this method is ill suited for susceptibility studies, which require hundreds and often thousands of samples to be examined.
A microtiter plate-based method has been introduced for the study of biofilm development. The method was successfully used to search for genes participating in the biofilm development of several gram-negative species (
21,
50). Wells of microtiter plates are inoculated with a bacterial suspension, and biofilms form on the surface of the wells. After a 24- to 48-h incubation, planktonic cells are removed by rinsing the wells. A solution of crystal violet is then added to the wells and stains the cells. The wells are then rinsed, and the bound dye is extracted with acetone-ethanol and quantified spectrophotometrically. This provides a quantitative measure of the mass of biofilm cells. It would be very useful to adapt this simple method to antimicrobial susceptibility measurements.
A promising apparatus for susceptibility testing is the Calgary Biofilm Device (
14). This disposable apparatus ingeniously combines a shearing force that makes a robust biofilm and a microtiter plate capability. The device looks like a 96-prong replicator with plastic pins. It inserts into a grooved tray that is filled with growth medium inoculated with cells. The apparatus is then placed on a tilting shaker platform, and the growing cell suspension washes the pins, on which biofilms grow. Importantly, any cell or cell mass that is not clinging well to the pin is washed away. As a result, one can form a robust biofilm that can be rinsed without loosing its integrity. After the biofilm is formed, the lid with pins can be placed into a microtiter plate for susceptibility testing. After a period of incubation with antibiotics, the cells can be dislodged from the pins by mild sonication and plated for determination of colony counts. The round pins do not make it easy to perform microscopic observations of the biofilms. One can envision a simple modification in which the pins are made flat and thin with a perforated or thinned base for easy detachment.
NATURE OF PERSISTERS
In 1944, Joseph W. Bigger of Trinity College (Dublin, Ireland), working in the command laboratory at York, United Kingdom, published a paper in
The Lancet that reported on two important discoveries (
7). According to Bigger, penicillin is a cidal rather than a bacteriostatic antibiotic, contrary to the prevailing opinion at the time; and treatment of a population of staphylococci with penicillin failed to sterilize the culture, leaving a small portion of cells that he aptly named “persisters”. Bigger estimated the incidence of persisters to be about 10
−6. In that pioneering but largely forgotten study, Bigger considered two main hypotheses: (i) persisters have a higher heritable resistance to growth inhibition by penicillin, and (ii) persisters are variants that have the same susceptibility to growth inhibition by penicillin as the bulk of the cells but are insensitive to killing by penicillin. Bigger showed that upon regrowth, persisters that survived treatment with penicillin produce populations indistinguishable from the original strain; they are similarly sensitive to growth inhibition and produce new persisters.
The nature of persistence is unknown, and not much has been done over the past half a century to study these very interesting cells that apparently play a crucial role in population survival. Lack of appreciation of the clinical significance of persisters is in part responsible for the paucity of knowledge. Difficulties in studying a very small part of a population that has transient peculiarities have also contributed to the current state of ignorance. Perhaps the realization that persisters are essentially responsible for the resistance of biofilms to killing will stimulate studies into the nature of persistence. At present, considerably more is known about what persisters are not rather than what they are. Persisters are not mutants. It can also be concluded that persisters do not represent a special stage in the cell cycle, which is the current popular explanation (
8,
19). At a rate of 10
−6, however, this distinct stage of the cell cycle should occupy 1.8 ms (30 min/10
6), which would call for an unrealistic synchronization of processes throughout the cell on a time scale comparable to that of a single turnover of an enzymatic reaction. Persisters are most likely not cells in a special dormant state of no growth, which has also been suggested (
29) (see below).
Obtaining empirical data on persisters should be relatively straightforward. It will be important to learn such basic facts as species-specific variations in persister prevalence rates, the dependence of the rate of persisters on growth conditions, the number of divisions required for the loss of persistence, whether or not persistence can be lost without undergoing division, how long persisters survive in the presence of antibiotics, and whether persisters are made of one type of cells or, rather, whether there are subpopulations of different kinds of persisters, each more resistant to killing by a particular type or subset of factors. It would be especially important to learn how the growth rate affects the resistance of persisters. For example, it is possible that these two factors act in synergy and that the resistance of persisters to killing is aided by conditions of slow growth.
GENES AFFECTING PERSISTENCE AND TOLERANCE
Even though the most basic facts about the physiology of persisters are not known, several genes strongly affecting the rate of persistence have been described (see reference
33 for a detailed review).
The first screen for genes that specifically affect persistence was performed by Moyed and Bertrand (
41). The rationale was to enrich an ethyl methanesulfonate-mutagenized population of
E. coli with cells that survived ampicillin treatment and then screen for colonies that produced larger numbers of ampicillin persisters. Only mutants whose growth was normally inhibited by ampicillin were examined further. This approach led to the identification of three independent
hip (high-level persistence) loci. All
hip mutants produced about 1,000-fold more persistent cells than the wild type did. One of the loci,
hipAB, was cloned and sequenced (
9,
42). This was the first report of bacterial genes specifically involved in the regulation of cell death. A knockout mutant of the wild-type
hipA gene did not have an apparent phenotype, while a
hipB knockout mutant was not obtained, indicating that a null mutant is nonviable. A mutant from which both
hipA and
hipB were deleted was obtained, and this strain had similar levels of persistence in the presence of penicillin as the wild type (
8). Biochemical studies have shown that HipB is a transcriptional repressor that binds to the promoter region of the
hip operon. HipB is a 10-kDa helix-turn-helix DNA binding protein that forms a dimer and forms a tight 1:1 complex with HipA. Moderate levels of expression of cloned wild-type HipA produced the same phenotype as the original
hip (
hipA or
hipB) mutation did; the numbers of cells that persisted after treatment with penicillin was increased (
19). The fact that a null
hipBmutation is likely lethal indicates that overexpression of HipA causes death. Indeed, a high level of expression of HipA from a controllable promoter inhibited cell growth, although cell survival was not examined under these conditions (
19). Apparently, the
hipAB locus has the potential to act both as an inhibitor of cell death and as a killing factor. It was suggested that
hipA or
hipB mutants have a decreased affinity for HipA or HipB binding and thus have a higher (and moderate) level of free HipA that protects cells from killing by ampicillin. Most importantly, the
hip mutants showed increased levels of resistance to factors unrelated to ampicillin. Mutated cells had a 1,000-fold higher survival rate after thymine starvation, which leads to DNA degradation (
58), and were more resistant to quinolone antibiotics, which target DNA gyrase and topoisomerase (
19,
70). Even more strikingly, the
hipmutation protected
htpR cells deficient in induction of heat shock proteins from killing by increased temperature (
58). In this case, the
hip mutation conferred the highest degree of protection: the number of
htpR cells decreased by 2 logs after a short incubation at 42°C, while virtually no decrease was observed for
htpR hipA cells. Mutants with mutations in
hipAB did not protect cells from kanamycin, another cidal factor that was tested. The fact that a mutation can increase the rate of persisters to 100% (as in the case of temperature resistance) suggests that persisters are not dormant and do not represent a special stage of the cell cycle.
A similar targeted search for persister (tolerance) genes was performed with
S. pneumoniae (
46). The same dual test that Moyed and colleagues used was applied to screen for mutants, saving those with increased resistance to killing by penicillin and those with unchanged susceptibility to growth inhibition by penicillin. One of the 17 mutants obtained in this screen appeared to have a mutation in a new sensory kinase, which was named VncS.
vncSmutants were reported to be resistant not only to cell wall inhibitors but also to aminoglycosides and quinolones. At the same time, growth of the
vncS mutant was inhibited by antibiotics as effectively as growth of the wild type, showing that antibiotics were able to act normally against their targets in
vncS mutant cells. In
S. pneumoniae, an autolysin (LytA) is responsible for autolysis, and
lytA mutants are resistant to killing by cell wall inhibitors like penicillin (
65) (antibiotics that are not cell wall inhibitors were not tested with the
lytAmutant). LytA was normally expressed in the
vncS strain. Apparently, VncS does not control the synthesis of LytA but, rather, regulates expression of an unknown factor that activates LytA in response to an antibiotic's action (
46). VncS is activated at least in part by an extracellular peptide pheromone (
45).
In addition to hipAB, several well-studied E. coli genes have also been reported to strongly affect cell survival in the presence of antibiotics.
DNA damage by mutagens (which include quinolone antibiotics) is sensed by the RecA protein, which becomes activated and induces hydrolysis and inactivation of the LexA repressor (
68). This releases LexA from the promoter regions of a number of
lex box genes and allows the expression of components of the SOS DNA repair response. LexA repressor inactivation also leads to the synthesis of a rapidly hydrolyzed SulA protein that inhibits cell division by binding to FtsZ, the protein that forms the division ring. SulA therefore acts as a checkpoint: it accumulates after exposure to DNA-damaging agents and inhibits cell division. Subsequently, upon DNA repair SulA is degraded by the Lon protease and cell division proceeds. This scenario suggests that without SulA, DNA will not be properly repaired prior to replication, leading to production of nonviable cells. Interestingly, this is not the case. A
sulA mutant of an otherwise normal strain (with a
lon+ background) had a 100-fold higher rate of survival against killing by mutagenic quinolones (
51). This experiment strongly suggests that the main role of SulA is not to aid repair but to trigger elimination of cells with serious defects in DNA from the population.
Another important locus that affects cell survival is
relA. It is well established that tolerance to killing by a wide variety of factors correlates inversely with the growth rate. Slow growth activates the RelA-dependent synthesis of ppGpp, which inhibits anabolic processes in bacterial cells (
13). Interestingly, ppGpp suppressed the activity of a major
E. coli autolysin, SLT (
6), which would make the cells more resistant to autolysis and could explain the mechanism of tolerance to antibiotics in slowly growing cells. While a mutation in
relA, the gene coding for ppGpp synthase, did not affect the growth rate, it made nongrowing cells sensitive to killing by antibiotics that inhibit cell wall synthesis (
57), although even in this mutant prolonged starvation led to the development of resistance. ppGpp inhibits peptidoglycan synthesis, which would explain the decreased levels of activity of cell wall synthesis inhibitors under starvation conditions. It would be interesting to learn whether
relAmutants also become sensitive to killing by other types of lethal factors that do not target the cell wall.
HOW TO ERADICATE BIOFILMS
The prognosis does not look good for the immediate future: too little is known about persisters to suggest ways of eradicating them. Knowing where to look for the cause of biofilm resistance, however, is a good place to start. Genes responsible for persistence can be identified (in addition to the examples discussed above), and these may serve as targets for drug discovery. Any inhibitor of a factor that causes persistence could then be combined with a conventional antibiotic such as a fluoroquinolone to eradicate a biofilm. Such a dual therapy is logistically similar to the currently used β-lactam–β-lactamase inhibitor combinations or MDR inhibitor-antibiotic combinations which are in development (
37,
56,
62). Both types of approaches are based on a combination of an antibiotic and a substance inhibiting the mechanism of resistance to this antibiotic.
Development of drugs disabling the persister phenotype is likely to provide an effective therapy for biofilm infections and other types of infections in which persisters are a problem, but this will take time. Meanwhile, a variety of approaches that can be used to fight or prevent biofilm infections are being tested.
The only specific antibiofilm therapy presently in use is based on the incorporation of antibiotics into the material of indwelling catheters (
16,
53,
61,
71). The combination of rifampin and minocycline is especially effective. This approach decreases the probability of colonization and is in essence a prophylactic measure. This seems to be a straightforward and useful approach, although it has obvious limitations. Bacteria resistant to the impregnated antibiotic will colonize the indwelling device; the method is probably limited to relatively short-term catheters and will not be effective for artificial joints or heart valves, nor does it address the issue of biofilm infections unrelated to indwelling devices.
Two interesting physical approaches to the eradication of biofilms are being developed: the use of an electromagnetic field (
38) or ultrasound (
55), both in conjunction with antibiotic therapy. These promising methods are in preclinical stages of development.
Biofilm development is an area of intense research (see reference
47 for a recent comprehensive review), and the components involved in development have been considered possible targets for therapy. Random transposon insertion libraries were used for a generalized screen for “biofilm genes” by detecting the ability of mutant clones to adhere to the wells of microtiter plates. This approach was pioneered by Pierre Genevaux and coworkers (
21) and was originally applied to
E. coli. Similar studies were then performed with a number of other species:
Pseudomonas fluorescens (
49),
P. aeruginosa (
48), and
Vibrio cholerae(
69). An independent study of
E. coli was done as well (
52). In all cases, biofilm formation was impaired in nonmotile mutants. Pili, although different kinds for each species, were found to facilitate initial adherence. Genes coding for the synthesis of exopolysaccharide were found to be necessary for biofilm formation in
V. cholerae. A detailed analysis of the dynamics of biofilm formation with some of these insertion mutants showed that motile cells are better at reaching the surface, accounting for the need for flagella. Pili are specialized attachment organelles and, not surprisingly, assist with biofilm formation. These findings confirmed previous observations that motility (
30,
31) and pili (
64) are needed for biofilm formation. Some other surface adhesion factors as well as regulators of expression of surface compounds were found to be involved in biofilm formation (
47).
Is the presence, then, of flagella, pili, and exopolysaccharide sufficient to build a biofilm? Perhaps exopolysaccharide alone is sufficient in species that lack flagella or pili? Interestingly, exopolysaccharide synthesis defects were found to prevent biofilm formation only in
V. cholerae and not the other species studied. This might be due to the redundancy of different polysaccharides. For example, alginate is formed copiously in some strains of
P. aeruginosa and is believed to contribute to the pathology of cystic fibrosis. However, strains deficient in alginate production use other exopolysaccharides to form biofilms. It is also important that the ability of cells to adhere to a surface strongly depends on the nature of the surface. For example, the presence of pili was found to actually inhibit the attachment of
P. aeruginosa to contact lenses (
20). It is clear that both the surface of the cell and the surface of the substratum determine the effectiveness of adhesion in biofilm formation. Numerous surface adhesins of pathogens, of which the pilus is only one example, will facilitate binding to host cells (
2,
40,
54) and abiotic surfaces (
27,
47). These adhesins might or might not play a role in biofilm formation on a particular artificial surface.
One limitation of the transposon insertion screening studies is that they test the mass of the cells making up the biofilm, which will not report defects in biofilm architecture. It was recently found that the quorum-sensing factor
N-(3-oxododecanoyl)-
l-homoserine lactone (HSL) is required for the formation of a biofilm with a complex “wild-type” architecture: rather loosely packed cell masses with a mushroom appearance with substantial amounts of exopolysaccharide and aqueous channels traversing the entire biofilm (
17). A
P. aeruginosa lasI mutant defective in HSL production formed thin, dense biofilms on a glass surface that were easily dislodged by sodium dodecyl sulfate (SDS), unlike the wild-type biofilms, which were not affected by SDS. We found that this mutant formed biofilms on polystyrene in the Calgary Biofilm Device that were not affected by SDS (
11). More importantly, the mutant biofilm showed the same level of resistance to ofloxacin as the wild type, suggesting that architecture or other properties of this defective biofilm do not affect its ability to produce persister cells and to resist killing by an antibiotic. The “mushroom” architecture of biofilms, with cell columns separated by water channels, evokes function. This would ease delivery of nutrients and release of metabolic products (
17). The sophisticated architecture in turn suggests that a dedicated program is in place to build a biofilm (
47). However, the usefulness of a well-structured biofilm compared to that of its flattened version has not been experimentally demonstrated.
This analysis brings me to an important question: are development proteins viable targets for antibiofilm drug discovery? Are antagonists of HSL good candidates for drug development? One problem with components like pili or flagella is that targeting of developmental components means that the therapy will provide a prophylaxis rather than a cure for a biofilm infection. The exopolysaccharide synthesis genes seem like a better potential choice as targets since these components are probably required for the maintenance of biofilm formation and not only for the initial steps of biofilm formation. However, redundancy of polysaccharides and the differences between the biosynthesis genes in various species is a serious limitation for possible drug development by use of this pathway as a target. Similarly, quorum-sensing factors vary among different species, and HSL does not appear to be required for the formation of a biofilm resistant to killing.
This analysis of options suggests that the development of a universal antibiofilm therapy, possibly on the basis of targeting of persister proteins, is a long-term project, yet a possible simple solution to biofilm infection follows directly from the dynamics of in vitro biofilm eradication. The rationale is to administer a cidal antibiotic, then withdraw it, and then add it again. The first application of antibiotic will eradicate the bulk of biofilm cells, leaving persisters. In a realistic example, ofloxacin decreases the size of a
P. aeruginosa biofilm from 10
8 cells to 10
5 persisters (
11). Withdrawal of the antibiotic will allow this persister population to start growing. Assume that after two divisions the persistence phenotype is lost. At this point, the new population of 4 × 10
5 cells will produce 40 persisters. A second application of antibiotic should then completely eradicate the biofilm. This type of a simple cyclical antibiotic regimen was proposed previously by Bigger (
7) for eradication of staphylococcal persisters. This approach might work in topical applications, in which the delivery of antibiotics can be well controlled. For example, biofilm infections are common in urinary catheters, into which a desired solution can be instilled.
P. aeruginosa biofilm infections of cystic fibrosis patients provide another example in which this approach might work well. Antibiotics can be delivered topically to cystic fibrosis patients as aerosols. The popular medication Tobra (PathoGenesis/Chiron) is a tobramycin aerosol. This antibiotic is very effective in eradicating planktonic cells, which explains the clinical usefulness of the preparation. However, as discussed above, biofilms are resistant to tobramycin. In a cyclical application, one would deliver an aerosol of a fluoroquinolone antibiotic like ciprofloxacin, which would penetrate the biofilm and kill the cells. A second antibiotic application after a minimal period of time that would be necessary for survivors to start growing and loose their persister phenotype could then eradicate the biofilm. The feasibility of a cyclical biofilm eradication approach will depend on the rate with which persisters lose resistance to killing and regenerate new persisters and on the ability to manipulate the antibiotic concentration. Development of resistance in a situation in which the antibiotic concentration is allowed to drop is a concern, but cycling of two different antibiotics could largely eliminate this problem. If this approach works for topical applications, it will encourage an inquiry into the possible use of cyclical treatment of systemic biofilms as well. It is entirely possible that successful cases of antimicrobial therapy of biofilm infections result from a fortuitous optimal cycling of an antibiotic concentration that eliminated first the bulk of the biofilm and then the progeny of the persisters that began to divide.
Another interesting possibility for biofilm elimination comes from the observations of biofilm self-destruction.
P. fluorescensreadily forms a biofilm in a well-oxygenated environment, such as near the liquid surface on a glass slide inserted vertically in a beaker. As the oxygen gets depleted by the growing biofilm mass, a specific exopolysaccharide lyase is induced and digests the biofilm matrix, liberating the cells (
1). The result is a striking, almost complete disappearance of the biofilm. The authors suggested that the degradation of the matrix serves two functions: it provides nutrients for the starving biofilm and liberates cells, allowing them to seek greener pastures. The nutrient limitation in this experiment comes from oxygen deficiency rather than carbon deficiency, and it remains unclear whether a biofilm will self-destruct in response to any type of energy (or essential nutrient) limitation. It seems reasonable to expect that this dramatic and so obviously useful (to humans as well) ability of a biofilm to self-destruct is not limited to oxygen deficiency. Disassembly of the biofilm could be exploited to treat infections. One approach would be to emulate energy deprivation by providing inhibitors of oxidative phosphorylation. Such substances are usually toxic, but a number of topical antimicrobials are membrane-acting agents. The quaternary ammonium compound benzalkonium chloride or the cationic base chlorhexidine are pertinent examples. Salicylate, widely used in food preservation, is an uncoupler. It might very well appear that some of the topical antimicrobials are causing biofilm self-destruction to a certain extent. However, it must be pointed out that the aim of conventional antimicrobial therapy is to deliver and maintain the drug at the maximally achievable and safe level. A high concentration of an antiseptic like chlorhexidine will simply kill the majority of cells, will probably leave the persisters largely intact, and will not cause biofilm self-destruction. Synthesis and export of lyase are required for biofilm degradation, but these will happen only under conditions that decrease the energy level and that do not completely inhibit protein synthesis. The same logic would apply to industrial biofilm eradication (cooling towers, pipes, etc.): it might appear that an optimal low level of a biocide will be more effective than a high dose for the treatment of biofilms. Another and possibly more productive approach would be to develop specific drugs that interact directly with the components of the biofilm self-destruction pathway. In an experiment that could serve as a model for this approach, expression of alginate lyase from a controllable promoter increased sloughing of cells from a colony of mucoid
P. aeruginosacells that overproduced alginate (
10). Genes controlling biofilm self-destruction might appear to be of more use than genes involved in biofilm formation.